董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Wensheng Liu | 男 | Chairman, Founder, Chief Executive Officer | 54 | 200.00万美元 | 4961.32 | 2024-04-11 |
| Biao Dai | 男 | Independent Director | 68 | 16.80万美元 | 未持股 | 2024-04-11 |
| Connie C. Hsu | 女 | Independent Director | 61 | 16.80万美元 | 未持股 | 2024-04-11 |
| Oseas Zuluaga | 男 | Independent Director | 50 | 未披露 | 未持股 | 2024-04-11 |
| Zhinan Yin | 男 | Independent Director | 59 | 未披露 | 未持股 | 2024-04-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Wensheng Liu | 男 | Chairman, Founder, Chief Executive Officer | 54 | 200.00万美元 | 4961.32 | 2024-04-11 |
| Tao Jin | 男 | ETAO China CEO | 56 | 未披露 | 未持股 | 2024-04-11 |
| Hui Wang | 男 | Chief Financial Officer | 56 | 未披露 | 未持股 | 2024-04-11 |
董事简历
中英对照 | 中文 | 英文- Wensheng Liu
-
Wensheng Liu自2018年Etao International Co., Ltd.成立以来，Wensheng Liu一直担任Etao International Co., Ltd.董事长兼首席执行官。Wensheng Liu拥有20多年的华尔街经验。在这些年里，他在摩根大通、纽约证券交易所、路透社、普华永道、花旗银行、摩根士丹利等机构从事技术咨询、审计以及投资和财务管理工作。作为实干家、演说家和思想家，他一直是一名连续创业者，具有被证明的领导力。他是WSHP资本创始人、华尔街黄埔中心总裁、美国教育中心董事总经理，并与他人共同创立了北京CSII软件有限公司。自2010年6月4日起，Liu先生担任Apollo Solar Energy，Inc.的首席财务官。自2009年5月至2010年5月，Liu先生担任总部位于中国的环境设备制造商Jiangsu Sanhuan Industry & Commerce Co Ltd.的首席财务官。从2004年1月至2007年12月，Liu先生担任纽约证券交易所审计和合规部助理副总裁。Liu先生自2005年起担任注册会计师。
Wensheng Liu,has been, as the founder, Etao International Co., Ltd. Chairman and Chief Executive officer since the inception of ETAO International Group in 2018. Mr. Liu has more than 20 years of Wall Street Experience. During these years he engaged in technical consulting, auditing, as well as investment and financial management at JPMorgan Chase, at the New York Stock Exchange, with Reuters, PricewaterhouseCoopers, Citibank, Morgan Stanley and other institutions. He has been a serial entrepreneur with proven leadership as a doer, speaker, and thinker. He was the founder of WSHP Capital, President of Wall Street Huangpu Center, Managing Director of American Education Center and he co-founded Beijing CSII Software Co. LTD. From June 4, 2010, Mr. Wilson Liu served as Chief Financial Officer of Apollo Solar Energy, Inc. From May 2009 to May 2010, Mr. Liu served as Chief Financial Officer of Jiangsu Sanhuan Industry & Commerce Co Ltd., a China-based environmental equipment manufacturer. From January 2004 through December 2007, Mr. Liu served as Assistant Vice President of the Audit and Compliance Department of the New York Stock Exchange. Mr. Liu has been a Certified Public Accountant since 2005. - Wensheng Liu自2018年Etao International Co., Ltd.成立以来，Wensheng Liu一直担任Etao International Co., Ltd.董事长兼首席执行官。Wensheng Liu拥有20多年的华尔街经验。在这些年里，他在摩根大通、纽约证券交易所、路透社、普华永道、花旗银行、摩根士丹利等机构从事技术咨询、审计以及投资和财务管理工作。作为实干家、演说家和思想家，他一直是一名连续创业者，具有被证明的领导力。他是WSHP资本创始人、华尔街黄埔中心总裁、美国教育中心董事总经理，并与他人共同创立了北京CSII软件有限公司。自2010年6月4日起，Liu先生担任Apollo Solar Energy，Inc.的首席财务官。自2009年5月至2010年5月，Liu先生担任总部位于中国的环境设备制造商Jiangsu Sanhuan Industry & Commerce Co Ltd.的首席财务官。从2004年1月至2007年12月，Liu先生担任纽约证券交易所审计和合规部助理副总裁。Liu先生自2005年起担任注册会计师。
- Wensheng Liu,has been, as the founder, Etao International Co., Ltd. Chairman and Chief Executive officer since the inception of ETAO International Group in 2018. Mr. Liu has more than 20 years of Wall Street Experience. During these years he engaged in technical consulting, auditing, as well as investment and financial management at JPMorgan Chase, at the New York Stock Exchange, with Reuters, PricewaterhouseCoopers, Citibank, Morgan Stanley and other institutions. He has been a serial entrepreneur with proven leadership as a doer, speaker, and thinker. He was the founder of WSHP Capital, President of Wall Street Huangpu Center, Managing Director of American Education Center and he co-founded Beijing CSII Software Co. LTD. From June 4, 2010, Mr. Wilson Liu served as Chief Financial Officer of Apollo Solar Energy, Inc. From May 2009 to May 2010, Mr. Liu served as Chief Financial Officer of Jiangsu Sanhuan Industry & Commerce Co Ltd., a China-based environmental equipment manufacturer. From January 2004 through December 2007, Mr. Liu served as Assistant Vice President of the Audit and Compliance Department of the New York Stock Exchange. Mr. Liu has been a Certified Public Accountant since 2005.
- Biao Dai
-
Biao Dai自2022年1月17日起担任独立董事。40多年来，Dai先生一直在国际和国内中国市场管理各种业务。他在医疗领域和大型海外跨国企业拥有丰富的投资经验。自2017年起，他一直担任有限公司的首席执行官。2001年至2017年，他担任Tasly Phar. International Co.， Ltd.首席执行官。自Tasly Phar. International Co.， Ltd.成立以来，他一直是该集团国际扩张的主要推动者，在非洲、欧洲和北美40个国家设立和管理了60多家分支机构和办事处。在此之前，他曾担任美国DHD医疗器械公司亚太区总监五年。Dai先生是一名医生，曾在华盛顿大学圣路易斯医学院做过三年的访问研究学者。他还在南京医科大学附属苏州医院进行临床研究。同时，Dai先生担任Tasly Healthpac Austration（自2016年起）、Tasly Vivacare Canada（自2018年起）和Tasly Shenzhen Netherlands（自2008年起）的董事。Dai先生在镇江医学院获得学士学位，在林肯大学商学院获得工商管理硕士学位。
Biao Dai,has served as an independent director since January 17, 2022. For over 40 years Mr. Dai has managed various business in both the international and domestic Chinese markets. He has extensive experience investments in the medical field and with large overseas multinational enterprises. Since 2017 he has served as the Chief Executive Officer of Tianjin Medical & Health Investment Co., Ltd. From 2001 to 2017 he served as the Chief Executive Officer of Tasly Phar. International Co., Ltd.. He was the principal driver of the international expansion of the Tasly Group from its inception, establishing and managing more than 60 branches and offices located in 40 countries in Africa, Europe and North America. Before that he was the Director of Asia-Pacific region for DHD Medical Device Company in the United States for five years. Mr. Dai is a physician and was a visiting research scholar for three years at Washington University of St. Louis Medical School. He also performed clinical research in Affiliated Suzhou Hospital of Nanjing Medical University. Concurrently, Mr. Dai serves as a Director for Tasly Healthpac Austration (since 2016), Tasly Vivacare Canada (since 2018) and Tasly Shenzhou Netherlands (since 2008). Mr. Dai received his Bachelor's degree from Zhenjiang Medical School and his Masters of Business Administration from the Lincoln University Business School. - Biao Dai自2022年1月17日起担任独立董事。40多年来，Dai先生一直在国际和国内中国市场管理各种业务。他在医疗领域和大型海外跨国企业拥有丰富的投资经验。自2017年起，他一直担任有限公司的首席执行官。2001年至2017年，他担任Tasly Phar. International Co.， Ltd.首席执行官。自Tasly Phar. International Co.， Ltd.成立以来，他一直是该集团国际扩张的主要推动者，在非洲、欧洲和北美40个国家设立和管理了60多家分支机构和办事处。在此之前，他曾担任美国DHD医疗器械公司亚太区总监五年。Dai先生是一名医生，曾在华盛顿大学圣路易斯医学院做过三年的访问研究学者。他还在南京医科大学附属苏州医院进行临床研究。同时，Dai先生担任Tasly Healthpac Austration（自2016年起）、Tasly Vivacare Canada（自2018年起）和Tasly Shenzhen Netherlands（自2008年起）的董事。Dai先生在镇江医学院获得学士学位，在林肯大学商学院获得工商管理硕士学位。
- Biao Dai,has served as an independent director since January 17, 2022. For over 40 years Mr. Dai has managed various business in both the international and domestic Chinese markets. He has extensive experience investments in the medical field and with large overseas multinational enterprises. Since 2017 he has served as the Chief Executive Officer of Tianjin Medical & Health Investment Co., Ltd. From 2001 to 2017 he served as the Chief Executive Officer of Tasly Phar. International Co., Ltd.. He was the principal driver of the international expansion of the Tasly Group from its inception, establishing and managing more than 60 branches and offices located in 40 countries in Africa, Europe and North America. Before that he was the Director of Asia-Pacific region for DHD Medical Device Company in the United States for five years. Mr. Dai is a physician and was a visiting research scholar for three years at Washington University of St. Louis Medical School. He also performed clinical research in Affiliated Suzhou Hospital of Nanjing Medical University. Concurrently, Mr. Dai serves as a Director for Tasly Healthpac Austration (since 2016), Tasly Vivacare Canada (since 2018) and Tasly Shenzhou Netherlands (since 2008). Mr. Dai received his Bachelor's degree from Zhenjiang Medical School and his Masters of Business Administration from the Lincoln University Business School.
- Connie C. Hsu
-
Connie C. Hsu自2022年1月17日起担任独立董事，并担任薪酬委员会主席。自2019年以来，她担任PLLC过敏和免疫专家首席执行官。在此之前，从2009年到2019年，她担任综合医疗服务部过敏科科长。她是美国过敏性哮喘和免疫学研究院（FAAAAI）的研究员，美国过敏性气喘和免疫学学院（FACAAI）的研究员和亚利桑那州过敏学会的成员。2010年，她被《凤凰》杂志评为过敏和免疫学专业的顶级医师。在过去的10年中，Hsu博士担任过敏和免疫专家首席执行官兼综合医疗服务部过敏和免疫部主任。此外，她还是亚利桑那州研究解决方案的首席执行官和首席研究员，也是亚利桑那州成人和儿童过敏协会的成员。她是纽约州立大学布法罗分校的过敏/免疫学研究员，圣路易斯华盛顿大学医学院的助理和内科住院医师。在此之前，她是中国上海济南医院的主治医师。在此之前，她在中国浙江武康医院实习。Hsu博士在浙江大学医学院获得医学博士学位，随后在上海第二医科大学获得免疫学住院医师资格，并在圣路克医院获得内科住院医师资格以及在纽约州立大学布法罗分校获得过敏/免疫学研究员资格。
Connie C. Hsu,has served as an independent director since January 17, 2022, and serves as the chairperson of the Compensation Committee. Since 2019, she served as the Chief Executive Officer of Allergy & Immunology Specialists, PLLC. Prior, from 2009 to 2019, she was the Chief of the allergy division at Integrated Medical Services. She is a fellow of American Academy of Allergy Asthma and Immunology (FAAAAI), a fellow of American College of Allergy Asthma and Immunology (FACAAI), and a member of the Arizona Allergy Society. In 2010 she was ranked by Phoenix Magazine as the top physician specializing in Allergy and Immunology. For the past 10 years Dr Hsu has served as CEO of Allergy & Immunology Specialists and Chief of the Allergy & Immunology Division, Integrated Medical Services. As well, she is CEO and Principal Investigator for Research Solutions of Arizona and member of Adult & Pediatric Allergy Associates, AZ. She was an Allergy/Immunology Fellow at the State University of New York at Buffalo, an Associate and Internal Medicine Resident at the Washington University School of Medicine, St. Louis. Prior to these roles she was an Attending Physician in Shanghai Jinan Hospital, China. Before that she practiced in Zhejiang Wukang Hospital, China. Dr. Hsu obtained her MD at Zhejiang University School of Medicine, then did a residency in immunology at Shanghai Second Medical University and an internal medicine residency at St. Luke's Hospital and a fellow ship in Allergy/Immunology at the State University of New York, Buffalo. - Connie C. Hsu自2022年1月17日起担任独立董事，并担任薪酬委员会主席。自2019年以来，她担任PLLC过敏和免疫专家首席执行官。在此之前，从2009年到2019年，她担任综合医疗服务部过敏科科长。她是美国过敏性哮喘和免疫学研究院（FAAAAI）的研究员，美国过敏性气喘和免疫学学院（FACAAI）的研究员和亚利桑那州过敏学会的成员。2010年，她被《凤凰》杂志评为过敏和免疫学专业的顶级医师。在过去的10年中，Hsu博士担任过敏和免疫专家首席执行官兼综合医疗服务部过敏和免疫部主任。此外，她还是亚利桑那州研究解决方案的首席执行官和首席研究员，也是亚利桑那州成人和儿童过敏协会的成员。她是纽约州立大学布法罗分校的过敏/免疫学研究员，圣路易斯华盛顿大学医学院的助理和内科住院医师。在此之前，她是中国上海济南医院的主治医师。在此之前，她在中国浙江武康医院实习。Hsu博士在浙江大学医学院获得医学博士学位，随后在上海第二医科大学获得免疫学住院医师资格，并在圣路克医院获得内科住院医师资格以及在纽约州立大学布法罗分校获得过敏/免疫学研究员资格。
- Connie C. Hsu,has served as an independent director since January 17, 2022, and serves as the chairperson of the Compensation Committee. Since 2019, she served as the Chief Executive Officer of Allergy & Immunology Specialists, PLLC. Prior, from 2009 to 2019, she was the Chief of the allergy division at Integrated Medical Services. She is a fellow of American Academy of Allergy Asthma and Immunology (FAAAAI), a fellow of American College of Allergy Asthma and Immunology (FACAAI), and a member of the Arizona Allergy Society. In 2010 she was ranked by Phoenix Magazine as the top physician specializing in Allergy and Immunology. For the past 10 years Dr Hsu has served as CEO of Allergy & Immunology Specialists and Chief of the Allergy & Immunology Division, Integrated Medical Services. As well, she is CEO and Principal Investigator for Research Solutions of Arizona and member of Adult & Pediatric Allergy Associates, AZ. She was an Allergy/Immunology Fellow at the State University of New York at Buffalo, an Associate and Internal Medicine Resident at the Washington University School of Medicine, St. Louis. Prior to these roles she was an Attending Physician in Shanghai Jinan Hospital, China. Before that she practiced in Zhejiang Wukang Hospital, China. Dr. Hsu obtained her MD at Zhejiang University School of Medicine, then did a residency in immunology at Shanghai Second Medical University and an internal medicine residency at St. Luke's Hospital and a fellow ship in Allergy/Immunology at the State University of New York, Buffalo.
- Oseas Zuluaga
-
Oseas Zuluaga，担任ETAO International Co. Ltd 。的独立董事和审计委员会主席。他自2017年起担任Revere Securities LLC的首席财务官。从2011年到2017年，他还担任Laidlaw & Company （f/k/a Sands Brothers & Co, Ltd）的首席财务官和执行财务副总裁。1996年至2001年，他担任Whale Securities/ Bluestone Capital Corp.的财务总监/职员会计/工资经理/应付账款经理。他是一个非常注重细节的人，以确保所有报告和文件的完全准确性而闻名。他拥有强烈的、自我激励的职业道德和以结果为中心的心态，并在证券和交易行业拥有不断进步的职业生涯。他于2002年毕业于Hunter College，获得会计与金融学士学位。
Oseas Zuluaga,serves as an Independent director of ETAO International Co. Ltd and Chairman of the Audit committee. He serves as Chief Financial Officer of Revere Securities LLC since 2017. From 2011 to 2017, he also served as Chief Financial Officer and Executive Vice President Finance -FINOP of Laidlaw & Company (f/k/a Sands Brothers & Co, Ltd). He served as Controller/Staff Accountant/Payroll Manager/Accounts Payable Manager of Whale Securities/ Bluestone Capital Corp. from 1996 to 2001. He is a highly detail-oriented with a reputation of ensuring total accuracy in all reports and documentation. He offers a strong, seif-motivated work ethic and results-focused mindset with a progressive career in the securities and trading industries. He graduated from Hunter College with Bachelor of Science in Accounting and Finance, 2002. - Oseas Zuluaga，担任ETAO International Co. Ltd 。的独立董事和审计委员会主席。他自2017年起担任Revere Securities LLC的首席财务官。从2011年到2017年，他还担任Laidlaw & Company （f/k/a Sands Brothers & Co, Ltd）的首席财务官和执行财务副总裁。1996年至2001年，他担任Whale Securities/ Bluestone Capital Corp.的财务总监/职员会计/工资经理/应付账款经理。他是一个非常注重细节的人，以确保所有报告和文件的完全准确性而闻名。他拥有强烈的、自我激励的职业道德和以结果为中心的心态，并在证券和交易行业拥有不断进步的职业生涯。他于2002年毕业于Hunter College，获得会计与金融学士学位。
- Oseas Zuluaga,serves as an Independent director of ETAO International Co. Ltd and Chairman of the Audit committee. He serves as Chief Financial Officer of Revere Securities LLC since 2017. From 2011 to 2017, he also served as Chief Financial Officer and Executive Vice President Finance -FINOP of Laidlaw & Company (f/k/a Sands Brothers & Co, Ltd). He served as Controller/Staff Accountant/Payroll Manager/Accounts Payable Manager of Whale Securities/ Bluestone Capital Corp. from 1996 to 2001. He is a highly detail-oriented with a reputation of ensuring total accuracy in all reports and documentation. He offers a strong, seif-motivated work ethic and results-focused mindset with a progressive career in the securities and trading industries. He graduated from Hunter College with Bachelor of Science in Accounting and Finance, 2002.
- Zhinan Yin
-
Zhinan Yin，担任ETAO International Co. Ltd的独立董事和公司治理与提名委员会主席。2013年至今，任暨南大学生物医学转化研究所教授、院长（国家长江学者）。他还担任中国珠海市人民医院首席学术督察。2007年至2011年，他担任南开大学生命科学学院院长兼教授。2001年至2007年，他担任耶鲁大学医学院风湿病科副教授（兼职）。1997年至2001年任耶鲁大学医学院风湿病学部博士后、副研究员。1992年至1994年，Yin先生是意大利Aviano （PN）肿瘤参考中心实验肿瘤学部门的研究员。从1988年到1992年，他是广州医学院微生物和免疫学系的助理教授。他于1984年获得中国湖北医科大学的医学博士学位，1988年获得中国上海第二医科大学的硕士学位，1997年获得德国柏林自由大学Klinikum Benjamin franklin的博士学位。
Zhinan Yin,serves as an independent director of ETAO International Co. Ltd and Chairman of the Corporate Governance & Nominating Committee. He is the professor and Dean (National Changjiang Scholar), The Biomedical Translational Research Institute, Jinan University, Guangzhou, China from 2013 to present. He also serves as Chief Academic Inspector of Zhuhai People's Hospital, P.R. China. H served as Dean and Professor, College of Life Sciences, Nankai University, P.R. China from 2007 to 2011. He was Associate Professor (Adjunct), Section of Rheumatology, Yale School of Medicine from 2001 to 2007. He was Postdoctoral Fellow and Associate Research Scientist, Section of Rheumatology, Yale School of Medicine from 1997 to 2001. During 1992 to 1994, Mr. Yin was a Research Fellow, Division for Experimental Oncology, Reference Center for Oncology, Aviano (PN), Italy. Mr. Yin was Assistant Professor, Department of Microbiology and Immunology, Guangzhou Medical College, Guangzhou, P.R. China from 1988 to 1992. Mr. Yin graduated with M.D. from Hubei Medical University, P.R. China in 1984, a M.S. degree from Shanghai Second Medical University, P.R. China in 1988 and Ph.D. from Klinikum Benjamin Frankin, Free University Berlin, Germany in 1997. - Zhinan Yin，担任ETAO International Co. Ltd的独立董事和公司治理与提名委员会主席。2013年至今，任暨南大学生物医学转化研究所教授、院长（国家长江学者）。他还担任中国珠海市人民医院首席学术督察。2007年至2011年，他担任南开大学生命科学学院院长兼教授。2001年至2007年，他担任耶鲁大学医学院风湿病科副教授（兼职）。1997年至2001年任耶鲁大学医学院风湿病学部博士后、副研究员。1992年至1994年，Yin先生是意大利Aviano （PN）肿瘤参考中心实验肿瘤学部门的研究员。从1988年到1992年，他是广州医学院微生物和免疫学系的助理教授。他于1984年获得中国湖北医科大学的医学博士学位，1988年获得中国上海第二医科大学的硕士学位，1997年获得德国柏林自由大学Klinikum Benjamin franklin的博士学位。
- Zhinan Yin,serves as an independent director of ETAO International Co. Ltd and Chairman of the Corporate Governance & Nominating Committee. He is the professor and Dean (National Changjiang Scholar), The Biomedical Translational Research Institute, Jinan University, Guangzhou, China from 2013 to present. He also serves as Chief Academic Inspector of Zhuhai People's Hospital, P.R. China. H served as Dean and Professor, College of Life Sciences, Nankai University, P.R. China from 2007 to 2011. He was Associate Professor (Adjunct), Section of Rheumatology, Yale School of Medicine from 2001 to 2007. He was Postdoctoral Fellow and Associate Research Scientist, Section of Rheumatology, Yale School of Medicine from 1997 to 2001. During 1992 to 1994, Mr. Yin was a Research Fellow, Division for Experimental Oncology, Reference Center for Oncology, Aviano (PN), Italy. Mr. Yin was Assistant Professor, Department of Microbiology and Immunology, Guangzhou Medical College, Guangzhou, P.R. China from 1988 to 1992. Mr. Yin graduated with M.D. from Hubei Medical University, P.R. China in 1984, a M.S. degree from Shanghai Second Medical University, P.R. China in 1988 and Ph.D. from Klinikum Benjamin Frankin, Free University Berlin, Germany in 1997.
高管简历
中英对照 | 中文 | 英文- Wensheng Liu
Wensheng Liu自2018年Etao International Co., Ltd.成立以来，Wensheng Liu一直担任Etao International Co., Ltd.董事长兼首席执行官。Wensheng Liu拥有20多年的华尔街经验。在这些年里，他在摩根大通、纽约证券交易所、路透社、普华永道、花旗银行、摩根士丹利等机构从事技术咨询、审计以及投资和财务管理工作。作为实干家、演说家和思想家，他一直是一名连续创业者，具有被证明的领导力。他是WSHP资本创始人、华尔街黄埔中心总裁、美国教育中心董事总经理，并与他人共同创立了北京CSII软件有限公司。自2010年6月4日起，Liu先生担任Apollo Solar Energy，Inc.的首席财务官。自2009年5月至2010年5月，Liu先生担任总部位于中国的环境设备制造商Jiangsu Sanhuan Industry & Commerce Co Ltd.的首席财务官。从2004年1月至2007年12月，Liu先生担任纽约证券交易所审计和合规部助理副总裁。Liu先生自2005年起担任注册会计师。
Wensheng Liu,has been, as the founder, Etao International Co., Ltd. Chairman and Chief Executive officer since the inception of ETAO International Group in 2018. Mr. Liu has more than 20 years of Wall Street Experience. During these years he engaged in technical consulting, auditing, as well as investment and financial management at JPMorgan Chase, at the New York Stock Exchange, with Reuters, PricewaterhouseCoopers, Citibank, Morgan Stanley and other institutions. He has been a serial entrepreneur with proven leadership as a doer, speaker, and thinker. He was the founder of WSHP Capital, President of Wall Street Huangpu Center, Managing Director of American Education Center and he co-founded Beijing CSII Software Co. LTD. From June 4, 2010, Mr. Wilson Liu served as Chief Financial Officer of Apollo Solar Energy, Inc. From May 2009 to May 2010, Mr. Liu served as Chief Financial Officer of Jiangsu Sanhuan Industry & Commerce Co Ltd., a China-based environmental equipment manufacturer. From January 2004 through December 2007, Mr. Liu served as Assistant Vice President of the Audit and Compliance Department of the New York Stock Exchange. Mr. Liu has been a Certified Public Accountant since 2005.- Wensheng Liu自2018年Etao International Co., Ltd.成立以来，Wensheng Liu一直担任Etao International Co., Ltd.董事长兼首席执行官。Wensheng Liu拥有20多年的华尔街经验。在这些年里，他在摩根大通、纽约证券交易所、路透社、普华永道、花旗银行、摩根士丹利等机构从事技术咨询、审计以及投资和财务管理工作。作为实干家、演说家和思想家，他一直是一名连续创业者，具有被证明的领导力。他是WSHP资本创始人、华尔街黄埔中心总裁、美国教育中心董事总经理，并与他人共同创立了北京CSII软件有限公司。自2010年6月4日起，Liu先生担任Apollo Solar Energy，Inc.的首席财务官。自2009年5月至2010年5月，Liu先生担任总部位于中国的环境设备制造商Jiangsu Sanhuan Industry & Commerce Co Ltd.的首席财务官。从2004年1月至2007年12月，Liu先生担任纽约证券交易所审计和合规部助理副总裁。Liu先生自2005年起担任注册会计师。
- Wensheng Liu,has been, as the founder, Etao International Co., Ltd. Chairman and Chief Executive officer since the inception of ETAO International Group in 2018. Mr. Liu has more than 20 years of Wall Street Experience. During these years he engaged in technical consulting, auditing, as well as investment and financial management at JPMorgan Chase, at the New York Stock Exchange, with Reuters, PricewaterhouseCoopers, Citibank, Morgan Stanley and other institutions. He has been a serial entrepreneur with proven leadership as a doer, speaker, and thinker. He was the founder of WSHP Capital, President of Wall Street Huangpu Center, Managing Director of American Education Center and he co-founded Beijing CSII Software Co. LTD. From June 4, 2010, Mr. Wilson Liu served as Chief Financial Officer of Apollo Solar Energy, Inc. From May 2009 to May 2010, Mr. Liu served as Chief Financial Officer of Jiangsu Sanhuan Industry & Commerce Co Ltd., a China-based environmental equipment manufacturer. From January 2004 through December 2007, Mr. Liu served as Assistant Vice President of the Audit and Compliance Department of the New York Stock Exchange. Mr. Liu has been a Certified Public Accountant since 2005.
- Tao Jin
Tao Jin，将担任Etao International Co., Ltd.的中国首席执行官，他在医疗保健和医疗行业的企业管理、VC和PE设置方面拥有30多年的运营经验。自2013年以来，他担任Ch-gemstone Capital的管理合伙人，Ch-gemstone Capital专注于药品和医疗领域，管理资产超过220亿元人民币。2009年至2013年，他担任昆武九鼎投资有限责任公司药品和医疗基金的首席执行官。1991年至2008年，他在一家国有医院担任研究员。他于2000年获得中国北京一所顶级医学院的药物管理硕士学位。
Tao Jin,is an executive with more than 30 years of operations experience on corporate management, VC & PE settings in healthcare and medical industries. Mr. Jin serves as managing partner of Ch-gemstone Capital with over 22 billion RMB AUM focus on Drugs and Medical fields since 2013. Mr. Jin served as CEO of Drugs and Medical fund of Kunwu JiuDing Investment LLC from 2009 to 2013. Mr. Jin worked as researcher in a state-owned hospital from 1991 to 2008. Mr. Jin obtained a master's in Drug Management in 2000 from a top medical school in Beijing, China.- Tao Jin，将担任Etao International Co., Ltd.的中国首席执行官，他在医疗保健和医疗行业的企业管理、VC和PE设置方面拥有30多年的运营经验。自2013年以来，他担任Ch-gemstone Capital的管理合伙人，Ch-gemstone Capital专注于药品和医疗领域，管理资产超过220亿元人民币。2009年至2013年，他担任昆武九鼎投资有限责任公司药品和医疗基金的首席执行官。1991年至2008年，他在一家国有医院担任研究员。他于2000年获得中国北京一所顶级医学院的药物管理硕士学位。
- Tao Jin,is an executive with more than 30 years of operations experience on corporate management, VC & PE settings in healthcare and medical industries. Mr. Jin serves as managing partner of Ch-gemstone Capital with over 22 billion RMB AUM focus on Drugs and Medical fields since 2013. Mr. Jin served as CEO of Drugs and Medical fund of Kunwu JiuDing Investment LLC from 2009 to 2013. Mr. Jin worked as researcher in a state-owned hospital from 1991 to 2008. Mr. Jin obtained a master's in Drug Management in 2000 from a top medical school in Beijing, China.
- Hui Wang
Hui Wang，将担任ETAO中国首席财务官和ETAO International Co. Ltd的临时首席财务官，王先生是一名高管，在医疗保健和医疗行业拥有30多年的财务，会计，企业管理内部控制，VC和PE设置。自2014年以来，他担任Ch-gemstone Capital的管理合伙人兼首席财务官，该公司专注于药品和医疗领域，管理资产超过220亿元人民币。2008年至2014年，他担任Suya会计有限责任公司华南地区合伙人。2003年至2007年，他担任北京伟迈电子（纳斯达克股票代码：VIMC）的高级会计经理。1995年至2003年，他担任李安达会计有限责任公司和无锡东林会计有限责任公司的合伙人。1992年至1995年，他担任中国华金电子集团的会计。他于1992年获得中国镇江江苏大学经济学学士学位。
Hui Wang,is an executive with more than 30 years of finance, accounting, internal control on corporate management, VC & PE settings in healthcare and medical industries. Mr. Wang serves as managing partner and CFO of Ch-gemstone Capital with over 22 billion RMB AUM focus on Drugs and Medical fields since 2014. Mr. Wang served as Partner of South China Region of Suya accounting LLC from 2008 to 2014. Wang served as Senior accounting manager of Beijing Vimicro Electronics (Nasdag: VIMC) from 2003 to 2007. Mr. wang served as Partner of Li An Da Accounting LLC and Wuxi Donglin Accounting LLC from 1995 to 2003. Mr. Wang served as accountant in China HuaJin Electronics Group from 1992 to 1995. Mr. Wang obtained a bachelor's degree in economics in 1992 from Jiangsu University, Zhenjiang, China.- Hui Wang，将担任ETAO中国首席财务官和ETAO International Co. Ltd的临时首席财务官，王先生是一名高管，在医疗保健和医疗行业拥有30多年的财务，会计，企业管理内部控制，VC和PE设置。自2014年以来，他担任Ch-gemstone Capital的管理合伙人兼首席财务官，该公司专注于药品和医疗领域，管理资产超过220亿元人民币。2008年至2014年，他担任Suya会计有限责任公司华南地区合伙人。2003年至2007年，他担任北京伟迈电子（纳斯达克股票代码：VIMC）的高级会计经理。1995年至2003年，他担任李安达会计有限责任公司和无锡东林会计有限责任公司的合伙人。1992年至1995年，他担任中国华金电子集团的会计。他于1992年获得中国镇江江苏大学经济学学士学位。
- Hui Wang,is an executive with more than 30 years of finance, accounting, internal control on corporate management, VC & PE settings in healthcare and medical industries. Mr. Wang serves as managing partner and CFO of Ch-gemstone Capital with over 22 billion RMB AUM focus on Drugs and Medical fields since 2014. Mr. Wang served as Partner of South China Region of Suya accounting LLC from 2008 to 2014. Wang served as Senior accounting manager of Beijing Vimicro Electronics (Nasdag: VIMC) from 2003 to 2007. Mr. wang served as Partner of Li An Da Accounting LLC and Wuxi Donglin Accounting LLC from 1995 to 2003. Mr. Wang served as accountant in China HuaJin Electronics Group from 1992 to 1995. Mr. Wang obtained a bachelor's degree in economics in 1992 from Jiangsu University, Zhenjiang, China.